文献速递肝病

添加支链氨基酸改善肝硬化肌少症患者肌肉质量:安慰剂对照试验

Adding Branched-Chain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients With Sarcopenia: A Placebo-Controlled Trial.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

这项初步、前瞻性、随机双盲研究纳入32例经CT诊断肌少症的肝硬化患者,在营养和体力活动干预12周基础上,比较安慰剂(17例)与支链氨基酸(BCAA,15例)的效果。结果显示仅BCAA组肌肉质量显著改善(43.7 vs 46 cm2/m2,P=0.023),整体63%患者肌肉质量改善且BCAA组更常见(83.3% vs 46.7%,P=0.056),两组肝衰弱指数均显著改善。

要点

  • BCAA组肌肉质量显著改善(43.7 vs 46 cm2/m2,P=0.023)。
  • 整体63%患者肌肉质量改善,BCAA组83.3% vs 安慰剂组46.7%(P=0.056)。
  • 两组肝衰弱指数均显著改善(整体4.2 vs 3.9,P<0.001)。

核心结论

  • BCAA补充可改善肝硬化肌少症患者的肌肉质量。

研究设计与样本

  • 初步、前瞻性、随机双盲安慰剂对照研究,纳入32例经CT诊断肌少症的肝硬化患者,随机分为安慰剂组17例和BCAA组15例。
  • 所有患者接受为期12周的营养和体力活动干预。
  • 研究方案在ClinicalTrials.gov注册(NCT04073693)。

主要发现

  • 治疗后仅BCAA组肌肉质量显著改善(43.7 vs 46 cm2/m2;P=0.023)。
  • 整体17例(63%)患者肌肉质量改善,BCAA组改善比例更高(83.3% vs 46.7%;P=0.056)。
  • 整体队列(n=32)肝衰弱指数在12周后显著改善(4.2 vs 3.9;P<0.001),安慰剂组(4.2 vs 3.8;P<0.001)和BCAA组(4.2 vs 3.9;P<0.001)均显著改善。
  • BCAA组锌水平升高幅度大于安慰剂组(Δ锌:12.3 vs 5.5;P=0.026)。
  • BCAA组白蛋白改善有更大趋势(Δ白蛋白:0.19 vs 0.04;P=0.091)。

临床怎么用

  • 对于肝硬化合并肌少症患者,在营养和体力活动干预基础上可考虑补充BCAA以改善肌肉质量。
  • BCAA补充可能有助于改善锌水平,并对白蛋白有改善趋势。

局限性

  • 本研究为初步试验,样本量较小(共32例)。
  • 肌肉质量改善比例的比较(P=0.056)未达到统计学显著性。
  • 白蛋白改善仅为趋势(P=0.091),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The effect of branched-chain amino acid (BCAA) supplementation on muscle mass in patients with cirrhosis and sarcopenia is unknown. METHODS: This is a pilot, prospective, randomized, and double-blind study of a cohort of 32 patients with cirrhosis and sarcopenia diagnosed by computed tomography scan who underwent a nutritional and physical activity intervention for 12 weeks. They were divided into 2 groups (placebo: 17 patients; BCAA: 15 patients). The study protocol was registered at ClinicalTrials.gov (NCT04073693). RESULTS: Baseline characteristics were similar in both groups. After treatment, only the BCAA group presented a significant improvement in muscle mass (43.7 vs 46 cm2/m2; P = 0.023). Seventeen patients (63%) presented improvement in muscle mass overall, which was more frequent in the BCAA group (83.3 vs 46.7%; P = 0.056). Regarding frailty, there was a significant improvement in the Liver Frailty Index in the global cohort (n = 32) after the 12 weeks (4.2 vs 3.9; P < 0.001). This difference was significant in both groups: in the placebo group (4.2 vs 3.8; P < 0.001) and in the BCAA group (4.2 vs 3.9; P < 0.001). After treatment, the BCAA group had a higher increase in zinc levels than the placebo group (Δzinc: 12.3 vs 5.5; P = 0.026). In addition, there was a trend for greater improvement of albumin levels in the BCAA group (Δalbumin: 0.19 vs 0.04; P = 0.091). DISCUSSION: BCAA supplementation improves muscle mass in cirrhotic patients with sarcopenia.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Hernández-Conde M, Llop E, Gómez-Pimpollo L, et al. Adding Branched-Chain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients With Sarcopenia: A Placebo-Controlled Trial. Am J Gastroenterol. 2021. PMID: 34074812. doi:10.14309/ajg.0000000000001301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。